PHILADELPHIA--(BUSINESS WIRE)--Patients with diabetes-associated wounds could receive faster and more effective treatment thanks to a non-invasive device that monitors wound healing and is one step closer to market. Emunamedica LLC, a Florida-based healthcare start-up, has licensed technology for a near-infrared wound monitor from Drexel University. The device was developed by Dr. Elisabeth Papazoglou and Dr. Leonid Zubkov of Drexel’s School of Biomedical Engineering, Science and Health Systems in collaboration with Dr. Michael S. Weingarten, M.D. of Drexel College of Medicine and their teams. The device received joint support from the University City Science Center’s QED Proof-of-Concept Program and from the Wallace H. Coulter Translational Research Program at Drexel University. It is the first technology supported by QED Program funding to be licensed.
To read the full, original article click on this link: Drexel University Wound Monitor Supported by QED Proof-of-Concept Program and Coulter Foundation Funding is Licensed | Business Wire
